Search | Clinical Trials Finder

Conditions: Lymphoma
Interventions: Fatigue Reduction Diet, General Health Curriculum; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Vaccine Reaction
Interventions: FMP013, ALFQ; Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive, Urge Incontinence
Interventions: Intra-detrusor injection of Onabotulinumtoxin-A; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-alcoholic Fatty Liver Disease, Childhood Obesity, Insulin Resistance
Interventions: Carbohydrate-restricted diet, Control, low-fat diet; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 9 Years to 17 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity
Interventions: filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 12 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertrophy, Left Ventricular
Interventions: carvedilol MR, atenolol, lisinopril; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 78
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more

Conditions: Ischemic Stroke
Interventions: Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase); Drug
Lead sponsor: Andrew D. Barreto, MD; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatocellular Carcinoma
Interventions: Durvalumab, Bevacizumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 34
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more

Conditions: Dry Eye Syndromes
Interventions: CP-690,550, Cyclosporine, CP-690,550 Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more

Conditions: Ischemic Stroke
Interventions: Albumin, Saline; Biological · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 83 Years
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 69
States / cities: Phoenix, Arizona • Tucson, Arizona • Concord, California + 48 more

Conditions: Diabetes, Foot Ulcer
Interventions: INTEGRA™ Flowable Matrix (Collagen); Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Rheumatoid Arthritis
Interventions: IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate; Biological · Drug · Dietary Supplement
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 18
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more

Conditions: Cigarette Smoking
Interventions: MASP+, Control; Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Urothelial Carcinoma
Interventions: DN24-02, Standard of Care; Biological · Other
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more

Conditions: Obesity
Interventions: 5 & 2 & 2 Plan, 4 & 2 & 1 Plan; Other
Lead sponsor: Medifast, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Owings Mills, Maryland

Conditions: Brain Activity, Appetite, Ingestive Behavior, Glucose Control, Cholesterol
Interventions: Dietary control of protein and fiber intake at breakfast; Other
Lead sponsor: Purdue University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: West Lafayete, Indiana • West Lafayette, Indiana

Conditions: Severe Sepsis With Septic Shock
Interventions: Interleukin-7, Placebo; Drug
Lead sponsor: Revimmune; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diet, Healthy, Food, Nutrition, Intensive Care, Abdominal Trauma, Surgery, Intra-abdominal Infection, Sepsis, Ischemic Bowel, Vascular, Penetrating Abdominal Trauma, Enteral Feeding, Oral
Interventions: Nutrition Ecosystem pathway, Comparator; Combination Product · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Idiopathic Membranous Nephropathy
Interventions: Rituximab, Cyclosporine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more

Conditions: Severe Sepsis, Acute Lung Injury
Interventions: High Dose Citrulline, Placebo, Low Dose Citrulline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 13 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Traumatic Brain Injury
Interventions: Ketogenic Diet; Other
Lead sponsor: Gillette Children's Specialty Healthcare; Other
Eligibility: 2 Years to 17 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Amyotrophic Lateral Sclerosis
Interventions: NP001, Placebo; Drug
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more

Conditions: Prostate Cancer
Interventions: Atkins Diet; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • Durham, North Carolina

Conditions: Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride, prednisone, rituximab, sargramostim, vincristine, Intervention/procedure, antibody therapy, biological therapy, chemotherapy, colony-stimulating factor therapy, cytokine therapy, monoclonal antibody therapy, non-specific immune-modulator therapy, therapeutic procedure, tumor cell derivative vaccine, vaccine therapy; Drug · Procedure
Lead sponsor: Favrille; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Beverly Hills, California • Chapel Hill, North Carolina

Search by objective public record fields.

Living Well With Lymphoma

A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

The CLEVER Study - Coreg And Left Ventricular Mass Regression

Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

Albumin in Acute Ischemic Stroke Trial

Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

Smoking, Stress, HIV and Mobile Technology

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans

Effects of Protein and Fiber at Breakfast on Appetite, Blood Sugar, and Cholesterol

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

The PASTDUe Nutrition Ecosystem Project (PASTDUe)

MEmbranous Nephropathy Trial Of Rituximab

Citrulline in Severe Sepsis

Ketogenic Diet Following Moderate to Severe Pediatric Traumatic Brain Injury

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Atkins Diet and Prostate Cancer Clinical Trial

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma